David Novak
Stock Analyst at Raymond James
(1.13)
# 3,650
Out of 4,944 analysts
9
Total ratings
44.44%
Success rate
-9.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Novak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Downgrades: Outperform | $74 | $13.94 | +430.85% | 6 | Dec 10, 2021 | |
| LPTX Leap Therapeutics | Maintains: Outperform | $25 → $35 | $0.34 | +10,224.48% | 2 | Mar 2, 2021 | |
| CBIO Crescent Biopharma | Maintains: Outperform | $300 → $270 | $13.95 | +1,836.18% | 1 | Feb 4, 2021 |
Zymeworks
Dec 10, 2021
Downgrades: Outperform
Price Target: $74
Current: $13.94
Upside: +430.85%
Leap Therapeutics
Mar 2, 2021
Maintains: Outperform
Price Target: $25 → $35
Current: $0.34
Upside: +10,224.48%
Crescent Biopharma
Feb 4, 2021
Maintains: Outperform
Price Target: $300 → $270
Current: $13.95
Upside: +1,836.18%